Applications of Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation
Applications of Near-infrared Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation: A Prospective Randomized Controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jianqiang Tang, Dr.
- Phone Number: +8613661090036
- Email: doc_tjq@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contact:
- Jianqiang Tang, Dr.
- Phone Number: +8613661090026
- Email: doc_tjq@hotmail.com
-
Principal Investigator:
- Jianqiang Tang, Dr.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged between 18 and 75 years
- Colonoscopic biopsy confirmed colorectal adenocarcinoma
- The tumor was located in the rectum or upper rectum, and the surgical method was Dxion
- No local complications before operation (no obstruction, incomplete obstruction, no massive active bleeding, no perforation, abscess formation, no local invasion)
- Preoperative imaging diagnosis was cT1-4aNxM0
- The hematopoietic functions of heart, lung, liver, kidney and bone marrow meet the requirements of surgery and anesthesia
- Sign the informed consent form
Exclusion Criteria:
- Previous surgical history of malignant colorectal tumors
- The surgical methods were combined abdominoperineal resection, Hartman operation and ISR operation
- There are contraindication of laparoscopic surgery, such as severe cardiopulmonary insufficiency
- Patients who have undergone multiple abdominal and pelvic surgeries or extensive abdominal adhesion
- Patients with intestinal obstruction, intestinal perforation, intestinal bleeding and other emergency operations
- ASA grade ≥IV and/or ECOG physical status score ≥2 points
- Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases can not tolerate surgery
- Have a history of serious mental illness
- Patients with uncontrolled infection before operation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Laparoscopic No. 253 lymph node dissection and preserving the LCA under fluorescence guidance.
Preoperatively, indoycine green fluorescent dye was injected into the anus to trace the No. 253 lymph nodes, and intraoperatively, arterial branching of the mesentery was performed by intravenous injection of fluorescent dye to preserve the left colic artery.
|
Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China).
This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
|
|
Active Comparator: Performing laparoscopic No. 253 lymph node dissection and preserving the LCA.
Conventional laparoscopic approach for dissection of the No. 253 lymph nodes and preservation of the left colic artery.
|
Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China).
This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
success rate of IMA fluorescence imaging
Time Frame: From the beginning to the end of the surgery.
|
ICG solution was prepared at a concentration of 2.5 g/L.
A dose of 0.05 mg-0.10 mg/kg body weight of ICG was administered intravenously through a peripheral or central vein.
Before the injection of ICG, the fluorescence laparoscope was set to the original fluorescence mode to monitor the IMA region in real-time.Record the success or failure rate of IMA fluorescence imaging in the observation group.
Classify the successful IMA fluorescence imaging results into four different types according to the Morro classification and calculate the proportion of each type in successful imaging.
|
From the beginning to the end of the surgery.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Left colic artery retention rate
Time Frame: From the beginning to the end of the surgery.
|
Recording whether the left colic artery is preserved during surger.
|
From the beginning to the end of the surgery.
|
|
Incidence of IMA bleeding events
Time Frame: From the beginning to the end of the surgery.
|
Document incidents of mesenteric artery or vein bleeding caused by vascular injury during surgery.
|
From the beginning to the end of the surgery.
|
|
No.253 lymph node dissection time
Time Frame: From the beginning to the end of the surgery.
|
Measured based on surgical videos.
|
From the beginning to the end of the surgery.
|
|
Operation time
Time Frame: From the beginning to the end of the surgery.
|
Data obtained from anesthesia records.
|
From the beginning to the end of the surgery.
|
|
Intraoperative blood loss
Time Frame: From the beginning to the end of the surgery.
|
Data obtained from anesthesia records.
|
From the beginning to the end of the surgery.
|
|
Protective ostomy rate
Time Frame: From the beginning to the end of the surgery.
|
Data obtained from surgical records.
|
From the beginning to the end of the surgery.
|
|
Complication rate within 30 days after operation
Time Frame: within 30 days after operation.
|
According to the Clavien-Dindo classification system, complications were categorized into five grades.
The postoperative status of each patient was recorded within 30 days, and the proportion of complications in each grade was calculated as a percentage of the total number of observations.
|
within 30 days after operation.
|
|
Assessment of postoperative anal function urinary function within 30 days
Time Frame: Assessment conducted once before surgery, on postoperative day 7, and on postoperative day 30.
|
Evaluation of Low Anterior Resection Syndrome (LARS) scale, assessed using the following scales at preoperative, postoperative day 7, and day 30.
Scores range from 0 to 42, with lower scores indicating better outcomes.
|
Assessment conducted once before surgery, on postoperative day 7, and on postoperative day 30.
|
|
Measurement of residual urine volume in the bladder.
Time Frame: On the day the catheter was removed after surgery.
|
Bladder residual urine volume was measured on the same day as catheter removal.
A bladder residual urine volume of less than 50 ml was considered indicative of good bladder function, while a volume greater than or equal to 50 ml was considered indicative of urinary retention.
|
On the day the catheter was removed after surgery.
|
|
Arterial development time
Time Frame: From the beginning to the end of the surgery.
|
Measured based on surgical videos.
|
From the beginning to the end of the surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NCC-4123
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.